Stay updated with breaking news from லிசி சீலி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
4Bio Capital 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round Press Release 1 March 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focused on discovering and developing innovative immunotherapies. 4BIO participated in the second closing of CARISMA’s $59 million Series B round, alongside founding investors IP Group, Inc. and Penn Medicine, joining the initial Series B investor syndicate of SymBiosis II, Solasta Ventures, Livzon Pharmaceuticals Group, AbbVie Ventures, HealthCap, Wellington Partners, TPG Biotech, Agent Capital and MRL Venture Fund. ....
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision s proprietary asset, SPVN06, and further pipeline development Paris, February 04, 2021 – SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the appointment of Dr Daniel C. Chung as Chief Medical Officer ( CMO ). Dr Chung brings a wealth of experience in successful ocular gene therapy development, having led the global medical strategy for ophthalmology at Spark Therapeutics ( Spark ), a leading rare disease gene therapy company, where he played a pivotal role in the clinical development and approval of Luxturna™, the first gene therapy to be approved in the US for a genetic disease. Spark was acquired by Roche in 2019 for $4.3 billion. ....
Renowned Pioneers in Ophthalmology Join SparingVision s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board Paris, January 29, 2021 - SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board ( SAB ) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving, Professor of University of California Davis School of Medicine and the former Director of the US National Eye Institute, and Prof. Botond Roska, co-director of the Institute of Molecular and Clinical Ophthalmology Basel and Professor at the Medical and Science Faculty of the University of Basel. ....
Appointment of Professor Akiko Iwasaki to Scientific Advisory Board December 18, 2020 02:00 ET | Source: 4Bio Capital 4Bio Capital Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University Principal investigator at the Howard Hughes Medical Institute Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19 18 December 2020 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB). Professor Iwasaki has made significant contributions towards understanding innate and adaptive immunity. Throughout her research career she has made major breakthroughs including the demonstration of tissue-specific properties of dendritic cells, how DNA vaccines e ....
4Bio Capital: Appointment of Professor Akiko Iwasaki to Scientific Advisory Board Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University Principal investigator at the Howard Hughes Medical Institute Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19 18 December 2020 LONDON & BOSTON - 4BIO Capital ( 4BIO or the Group ), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB). Professor Iwasaki has made significant contributions towards understanding innate and adaptive immunity. Throughout her research career she has made major breakthroughs including the demonstration of tissue-specific properties of dendritic cells, how DNA vaccines elicit an immune response, and being the first group to create a mouse model of vaginal Zika infection. She ....